Titre : Protéines à répétitions de séquences bêta-transducine

Protéines à répétitions de séquences bêta-transducine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines à répétitions de séquences bêta-transducine : Questions médicales les plus fréquentes", "headline": "Protéines à répétitions de séquences bêta-transducine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines à répétitions de séquences bêta-transducine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines à répétitions de séquences bêta-transducine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines F-box", "url": "https://questionsmedicales.fr/mesh/D044783", "about": { "@type": "MedicalCondition", "name": "Protéines F-box", "code": { "@type": "MedicalCode", "code": "D044783", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.157.169" } } }, "about": { "@type": "MedicalCondition", "name": "Protéines à répétitions de séquences bêta-transducine", "alternateName": "beta-Transducin Repeat-Containing Proteins", "code": { "@type": "MedicalCode", "code": "D044844", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard A Cerione", "url": "https://questionsmedicales.fr/author/Richard%20A%20Cerione", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA; Department of Molecular Medicine, Cornell University, Ithaca, NY 14853, USA. Electronic address: rac1@cornell.edu." } }, { "@type": "Person", "name": "Yang Gao", "url": "https://questionsmedicales.fr/author/Yang%20Gao", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Sekar Ramachandran", "url": "https://questionsmedicales.fr/author/Sekar%20Ramachandran", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Jon W Erickson", "url": "https://questionsmedicales.fr/author/Jon%20W%20Erickson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Yeonji Chang", "url": "https://questionsmedicales.fr/author/Yeonji%20Chang", "affiliation": { "@type": "Organization", "name": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.", "datePublished": "2023-01-02", "url": "https://questionsmedicales.fr/article/36595589", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00458" } }, { "@type": "ScholarlyArticle", "name": "Psychomodulatory substances: New legislative framework for control of psychoactive substances in Czechia.", "datePublished": "2024-10-09", "url": "https://questionsmedicales.fr/article/39388916", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2024.104603" } }, { "@type": "ScholarlyArticle", "name": "Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.", "datePublished": "2023-06-09", "url": "https://questionsmedicales.fr/article/37348270", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.110819" } }, { "@type": "ScholarlyArticle", "name": "The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35947832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00433" } }, { "@type": "ScholarlyArticle", "name": "Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents.", "datePublished": "2024-05-31", "url": "https://questionsmedicales.fr/article/38818605", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/jme.2024.60" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines de transport", "item": "https://questionsmedicales.fr/mesh/D002352" }, { "@type": "ListItem", "position": 5, "name": "Protéines F-box", "item": "https://questionsmedicales.fr/mesh/D044783" }, { "@type": "ListItem", "position": 6, "name": "Protéines à répétitions de séquences bêta-transducine", "item": "https://questionsmedicales.fr/mesh/D044844" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines à répétitions de séquences bêta-transducine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines à répétitions de séquences bêta-transducine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines à répétitions de séquences bêta-transducine", "description": "Comment diagnostiquer une anomalie des protéines bêta-transducine ?\nQuels tests sont utilisés pour évaluer les protéines bêta-transducine ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nY a-t-il des marqueurs spécifiques pour ces protéines ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels symptômes sont associés aux dysfonctionnements des protéines ?\nLes symptômes sont-ils toujours présents ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes évoluent-ils avec le temps ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines à répétitions de séquences bêta-transducine", "description": "Peut-on prévenir les anomalies des protéines bêta-transducine ?\nY a-t-il des mesures préventives recommandées ?\nLes antécédents familiaux influencent-ils la prévention ?\nLe dépistage prénatal est-il possible ?\nLes vaccinations peuvent-elles aider ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels traitements sont disponibles pour les anomalies protéiques ?\nLa physiothérapie est-elle utile ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements peuvent-ils guérir les anomalies ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines à répétitions de séquences bêta-transducine", "description": "Quelles complications peuvent survenir avec ces anomalies ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle dans le risque ?\nLes habitudes de vie influencent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes facteurs de risque sont-ils modifiables ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Controlled+Substances&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines bêta-transducine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des analyses protéomiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les protéines bêta-transducine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de Western blot et des techniques de spectrométrie de masse sont courants." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être nécessaires pour évaluer l'expression des protéines dans les tissus." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces protéines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs spécifiques peuvent être identifiés par des anticorps ciblés." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à visualiser des anomalies associées, mais pas directement les protéines." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux dysfonctionnements des protéines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, incluant des troubles neurologiques et des anomalies métaboliques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains individus peuvent être asymptomatiques malgré des anomalies protéiques." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la vision et des problèmes de coordination peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes évoluent-ils avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent s'aggraver ou évoluer selon la gravité de l'anomalie." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent ressembler à ceux d'autres troubles neurologiques ou métaboliques." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des protéines bêta-transducine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives recommandées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils sur le mode de vie sain et le suivi médical régulier sont recommandés." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "Le dépistage prénatal est-il possible ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage prénatal peut identifier certaines anomalies génétiques." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne préviennent pas directement les anomalies protéiques, mais protègent la santé générale." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies protéiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie génique et des médicaments ciblés." } }, { "@type": "Question", "name": "La physiothérapie est-elle utile ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut aider à améliorer la fonction motrice et la coordination." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques évaluent de nouvelles approches thérapeutiques pour ces conditions." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient." } }, { "@type": "Question", "name": "Les traitements peuvent-ils guérir les anomalies ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements peuvent améliorer les symptômes, mais une guérison complète est rare." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces anomalies ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques graves et des déficits fonctionnels." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anomalies peuvent augmenter le risque de maladies métaboliques et cardiovasculaires." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement réduire la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des interventions thérapeutiques adaptées." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains risques augmentent avec l'âge, notamment pour les maladies dégénératives." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut exacerber les risques associés aux anomalies protéiques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou à des agents chimiques peut augmenter le risque." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils modifiables ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certains facteurs, comme le mode de vie, sont modifiables, d'autres non." } } ] } ] }

Sources (10000 au total)

A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.

The purpose of this study is to identify the risk factors for prolonged opioid use after surgery in geriatric hip fracture patients and the effects of prolonged use on mortality and readmission rates.... An institutional registry was queried for all patients older than 65 years who underwent surgical treatment of a hip fracture between January 2016 and June 2017. Using the Controlled Substance Utiliza... Of 500 patients who underwent hip-fracture surgery during the study period, a total of 322 had complete Controlled Substance Utilization Review and Evaluation System data. 36.0% (116) were OE, and 64.... Opioid use in geriatric hip fracture patients is high both preoperatively and postoperatively. Opioid exposed patients and patients on antidepressants are more likely to continue opioids at 6 months. ... Level III....

Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.

Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team ... To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription.... We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in ... Of n=40 pharmacies, one or more of the requested controlled substances could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfe... The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in t...

The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.

The United States opioid epidemic is a well-documented crisis stemming from increased prescriptions of narcotics. Online prescription drug monitoring programs (PDMPs) are a potential resource to mitig... Patients who underwent a single-level lumbar fusion between August 27, 2017, and August 31, 2020, were identified and placed categorically into one of two cohorts: an "early adoption" cohort, Septembe... No significant difference was observed in preoperative opioid prescriptions between the early and late adoption cohorts. The late adoption group independently predicted decreased postoperative opioid ... PDMP implementation was associated with decreased postoperative opioid prescription patterns but not preoperative opioid prescribing behaviors.... 4....

Real or fake? Sourcing and marketing of non-prescribed benzodiazepines amongst two samples of people who regularly use illicit drugs in Australia.

There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investig... Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribe... Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/o... Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While ...

Effect of Integrating Access to a Prescription Drug Monitoring Program Within the Electronic Health Record on the Frequency of Queries by Primary Care Clinicians: A Cluster Randomized Clinical Trial.

Tools that are directly integrated with the electronic health record (EHR) workflow can reduce the hassle cost of certain guideline-concordant practices, such as querying a prescription drug monitorin... To investigate the effect of integrating access to a PDMP within the EHR on the frequency of program queries by primary care clinicians.... The PRINCE (Prescribing Interventions for Chronic Pain Using the Electronic Health Record) randomized trial used a factorial cluster design at the clinic level in 43 primary care clinics in Minnesota.... Single sign-on access to the Minnesota PDMP was integrated into the EHR, allowing clinicians to query a patient's controlled substance prescription and dispensing history as recorded in the Minnesota ... Monthly PDMP query counts for primary care clinicians, overall and by modality (EHR-based, web-based, via a clinical delegate), adjusted for clinician characteristics, including type (physician, nurse... Of the 43 participating clinics with 309 clinicians, 21 clinics with 161 clinicians (102 [63.4%] women; 114 [70.8%] physicians; tenure, 10.6 [4.4] years) received the PDMP integration intervention. Ba... This cluster randomized clinical trial found that integrating access to the PDMP in the EHR increased PDMP-querying rates, suggesting that direct access reduced hassle costs and can dramatically impro... ClinicalTrials.gov Identifier: NCT04601506....

Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.

While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool ... Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant... There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific t... Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities....

Review and inventory of 911 Good Samaritan Law Provisions in the United States.

911 Good Samaritan Laws (GSLs) confer limited legal immunity to bystanders in possession of controlled substances who report emergency overdoses. While these laws may decrease opioid overdose mortalit... We identified all state GSLs and their legislative history, characterizing features into four categories using a novel framework: breadth of protected activities, burden placed on Good Samaritans, str... GSLs vary substantially across states and time. Protections depend on the quantity of substances involved and may extend to the person experiencing the overdose or persons reporting their own overdose... States offer Good Samaritans substantially different protections even when the statutes confer nominally comparable immunities. Accommodating this heterogeneity will enhance the validity of future stu...